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ABSTRACT
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes
breathlessness and cough that worsen over time, limiting daily activities and negatively impacting quality
of life. Although treatments are now available that slow the rate of lung function decline, trials of these
treatments have failed to show improvement in symptoms or quality of life. There is an immediate unmet
need for evidenced-based interventions that improve patients’ symptom burden and make a difference to
everyday living. This study aims to assess the feasibility of conducting a definitive randomised controlled
trial of a holistic, complex breathlessness intervention in people with IPF.
Methods and analysis: The trial is a two-centre, randomised controlled feasibility trial of a complex
breathlessness intervention compared with usual care in patients with IPF. 50 participants will be recruited
from secondary care IPF clinics and randomised 1:1 to either start the intervention within 1 week of
randomisation (fast-track group) or to receive usual care for 8 weeks before receiving the intervention
(wait-list group). Participants will remain in the study for a total of 16 weeks. Outcome measures will be
feasibility outcomes, including recruitment, retention, acceptability and fidelity of the intervention. Clinical
outcomes will be measured to inform outcome selection and sample size calculation for a definitive trial.
Ethics and dissemination: Yorkshire and The Humber – Bradford Leeds Research Ethics Committee
approved the study protocol (REC 18/YH/0147). Results of the main trial and all secondary end-points
will be submitted for publication in a peer-reviewed journal.
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Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. This study
protocol describes the BREEZE-IPF study: a feasibility, randomised controlled trial of a holistic,
complex breathlessness intervention in IPF. http://bit.ly/33eF9im
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with an incidence in the UK
of around 8.04 per 100000 person-years [1]. Breathlessness and cough are common symptoms in IPF and
typically worsen over time, limiting daily activities and impacting quality of life [2]. The impact of
breathlessness on IPF patients can be profound. In addition to the detrimental impact on quality of life,
chronic breathlessness is associated with anxiety and depression [3] and reduced survival [4]. The median
survival is 3 years from diagnosis and until recently there were no disease-modifying therapies [5]. Two
therapies are now available that slow the rate of lung function decline [6, 7]; however, trials have failed to
show improvement in symptoms or quality of life [6, 7]. This emphasises the importance of a holistic
approach to patient management, and the complex interplay between symptoms and disease outcomes.
There is therefore an immediate unmet need for evidenced-based interventions that improve patients’
symptom burden and make a difference to everyday living.
Pulmonary rehabilitation improves IPF patients’ exercise capacity, symptoms and quality of life [8–12].
However, despite featuring in national guidelines, access to programmes varies across the UK and
rehabilitation programmes are generally tailored to patients with chronic obstructive pulmonary disease.
While pulmonary rehabilitation is a core component of IPF patients’ management, it is not suitable for or
tolerated by all patients and therefore many remain unable to access evidence-based treatment for their
symptoms.
It is recommended that IPF patients should have access to palliative care services to support symptom
management. Palliative breathlessness interventions can be pharmacological and/or nonpharmacological.
However, their effectiveness in IPF patients is unknown. Nonpharmacological breathlessness interventions
have been studied in patients with chronic breathlessness caused by cardiorespiratory diseases, with
benefits observed in terms of reduced distress due to breathlessness and increased breathlessness mastery
[13–15]. Subgroup analysis revealed patients with nonmalignant diseases who received a breathlessness
intervention as part of a randomised controlled trial had prolonged survival [13]. However, patients with
interstitial lung disease are under-represented in these studies.
Evidence of the efficacy of palliative care breathlessness strategies in IPF patients is limited [16]. The poor
prognosis, variable disease trajectory and absence of any existing, widely accessible, evidence-based
treatment to improve patients’ symptoms set IPF apart from other causes of chronic breathlessness. Studies
in this patient group are needed to help clinicians and commissioners identify the efficacy, reproducibility
and cost-effectiveness of an intervention to improve breathlessness management in IPF patients.
Dove House Hospice (Hull, UK) provides a specialist breathlessness service led by an experienced
respiratory physiotherapist. Patients attending the service undergo a comprehensive assessment prior to
receiving training in four breathlessness management techniques. As part of routine care, patients
attending the Hull breathlessness service complete numerical rating scales (NRSs) scored 0–10 before and
after attendance to assess the following characteristics of breathlessness: severity, distress and ability to
cope. An evaluation of 22 consecutive IPF patients showed significant improvements in terms of average
breathlessness in the past 24 h (NRS change: −0.27, 95% CI −0.52–−0.03; p=0.03), worst breathlessness in
the past 24 h (NRS change: −1.05, 95% CI −1.47–−0.6; p<0.01), distress caused by breathlessness (NRS
change: −0.95, 95% CI −1.21–−0.61; p<0.01) and perceived ability to cope with breathlessness (NRS
change: 1.00, 95% CI 0.68–1.32; p<0.01) [17]. A similar breathlessness intervention has been studied in a
multicentre trial in malignant disease, demonstrating that the breathlessness intervention can effectively be
implemented across different centres [15]. The scalability of this breathlessness intervention and
preliminary data suggesting benefit in an IPF cohort led us to select this intervention for this trial.
As large-scale trials of a complex breathlessness intervention have not been attempted in this patient group
to date, the BREEZE-IPF study is designed to assess the feasibility of conducting a future definitive study.
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University of York, York, UK. 3Dove House Hospice Palliative Care Physiotherapy Team, NHS Humber
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6Centre for Health Economics, University of York, York, UK. 7Hull Health Trials Unit, University of Hull,
Kingston upon Hull, UK.
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Study aim and objectives
The BREEZE-IPF study aims to address the following areas of uncertainty relating to the design and
conduct of a definitive, phase 3, randomised controlled trial of a holistic complex breathlessness
intervention in people with IPF.
Recruitment
We will identify the eligibility/consent ratio, recruitment rate and participant retention rate to inform the
number of sites needed to enrol sufficient participants within an acceptable timeline. We will assess
acceptability of recruitment, randomisation and trial processes from the patients’ perspective.
Intervention
We will assess the acceptability and fidelity of the intervention by measuring adherence in delivery and
uptake, and via patient and carer interviews. This will include documenting aspects of breathlessness
interventions used in the control arm provided ad hoc, e.g. breathing techniques and use of a hand-held fan.
Data quality
We will assess the amount and pattern of missing data for study measures and completion of
questionnaires and other study procedures at each time-point. Data variability across the range of outcome
measures will also be assessed. These findings will inform the choice of primary and secondary outcomes
for the definitive trial.
Outcomes
We will determine which is the most appropriate primary outcome and agree other study measures for the
definitive trial by identifying: 1) patient views about relevance, importance and acceptability of
questionnaires or other measures (qualitative interview data); 2) data completion; and 3) data variability
for potential primary outcome measures to inform sample size calculation for the definitive trial.
Health economic assessment
We will assess the feasibility of collecting the data required to undertake a cost-effectiveness analysis in the
definitive trial.
Methods and analysis
Design
The trial is a feasibility, wait-list design, randomised controlled trial of a complex breathlessness
intervention compared with usual care in patients with IPF and chronic breathlessness. Participants will be
randomised 1:1 to start the intervention within 1 week of randomisation (fast-track group) or to receive
usual care for 8 weeks before receiving the intervention (wait-list group). Participants will remain in the
study for 16 weeks. A wait-list design was selected to ensure that all participants will be able to access the
breathlessness intervention during the study. The wait-list period was chosen based on feedback from
patients, their carers and healthcare professionals.
This feasibility trial is being conducted in two centres to reflect the different clinical environments where
IPF patients are managed in the UK. One site is a specialist interstitial lung disease centre and the other
centre is a rural district general hospital. The first patient was randomised in August 2018, with a
recruitment target of 50 patients over a period of 18 months.
The trial design and procedures are outlined in the study flowchart (figure 1) and schedule of events
(table 1).
Study population
Participants will be identified through participating site outpatient departments, interstitial lung disease
multidisciplinary team (MDT) meetings and research databases. Clinicians working in study sites will be
trained in the study protocol, including inclusion and exclusion criteria.
Eligible patients will be aged ⩾50 years, have IPF diagnosed by an MDT and experience chronic
breathlessness (defined as modified Medical Research Council grade 3 or 4 breathlessness that persists despite
optimal treatment of the underlying pathophysiology and is causing disability [18]). Participants are required
to have oxygen saturations of ⩾90% breathing room air or on their usual flow rate of supplemental oxygen.
Participants will be considered unable to take part if they: 1) have another significant cardiorespiratory
disease considered to be the primary cause of their breathlessness; 2) have completed pulmonary
rehabilitation or attended a breathlessness clinic within 3 months of enrolment; or 3) are unable or
unwilling to consent or complete study procedures.
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Sample size
Since this is a feasibility study, a formal sample size calculation has not been performed. We will recruit 50
patients over 18 months, 25 in each arm, which will be sufficient to assess the feasibility parameters.
Recruitment and consent
Participants will be identified by their usual care teams and provided with information about the study.
Potential participants will be given time to consider before agreeing to screening. Randomisation will
occur after eligibility is confirmed and informed consent is obtained.
Randomisation and blinding
Randomisation will be at the individual level using a commercial web-based randomisation system.
Participants will be randomised in a 1:1 ratio using random permuted blocks, fast-track intervention to
wait-list intervention, stratified by site. The randomisation sequence will be prepared by an independent
statistician from the Hull Health Trials Unit; all trial staff and sites will remain blinded to the sequence. It
is not possible to blind either patients, clinicians or trial staff to the treatment group allocation.
Intervention
The breathlessness intervention is delivered during three consultations with a trained practitioner
(physiotherapist, nurse specialist and/or occupational therapist). The first two consultations are conducted
face-to-face, last ∼1 h and take place 1 week apart. A final telephone consultation is conducted 1 week
later lasting 10–15 min. The intervention is holistic and is therefore tailored by the therapist to address the
patient’s individual needs. However, the following core aspects of breathlessness management will be
delivered to all participants: 1) breathing control techniques; 2) instructions on using a hand-held fan
(a fan will be provided); 3) pacing and breathlessness management during everyday activities, including
positions for recovery from exertional breathlessness and information on the importance of exercise; and
4) techniques to promote relaxation and manage anxiety and panic.
Recruitment and
screening
RandomisationFast-track group
Intervention (day 0–21)
  Breathlessness clinic attendance
  Two clinic visits and one
    telephone call
Intervention (day 56–77)
  Breathlessness clinic attendance
  Two clinic visits and one
    telephone call
Day 28
  Questionnaires
  ISWT
  Activity monitoring
Day 56
  Questionnaires
  ISWT
  Activity monitoring
  PFTs
Day 84
  Questionnaires
  ISWT
  Activity monitoring
Day 112
  Questionnaires and survey#
  ISWT
  Activity monitoring
  PFTs
Day 28
  Questionnaires
  ISWT
  Activity monitoring
Day 56
  Questionnaires
  ISWT
  Activity monitoring
  PFTs
Day 84
  Questionnaires
  ISWT
  Activity monitoring
Day 112
  Questionnaires and survey#
  ISWT
  Activity monitoring
  PFTs
Wait-list group
Day –1
  Questionnaires
  Baseline ISWT
Day –8
  Consent
  Screening
  PFTs
  ISWT (practice)
  Activity monitoring
Breathlessness
intervention
Breathlessness
intervention
Follow-up visit
Follow-up visit
Follow-up visit
Follow-up visit
Follow-up visit
Final visit
Follow-up visit
Final visit
Usual care
FIGURE 1 Feasibility wait-list study flowchart. PFT: pulmonary function test; ISWT: incremental shuttle walk
test. #: a study experience survey will be sent to participants on completion of the study or, if participants
discontinue the study early, as soon after withdrawal as practical.
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All participants will be given bespoke breathlessness intervention leaflets (based on the information leaflets
created by the Breathlessness Intervention Service at Addenbrooke’s Hospital, Cambridge, UK, with
permission) that cover the following breathlessness management techniques: 1) the hand-held fan;
2) breathing control and techniques to ease breathlessness; 3) positions to ease breathlessness; 4) managing
thoughts about breathlessness; 5) relaxation; 6) conserving energy levels; and 7) exercise.
Delivery of the core components of the breathlessness intervention and provision of the breathlessness
leaflets will be recorded to ensure intervention fidelity.
Outcomes and assessments
The following three feasibility outcomes will be assessed.
1) Recruitment: eligibility to consent ratio, recruitment rate and retention/follow-up rates at each
time-point: 4, 8, 12 and 16 weeks.
2) Data quality: completion of clinical outcomes (questionnaires and other assessments) at each time-point
(baseline, 4, 8, 12 and 16 weeks) and patterns of missing data for the study measures.
3) Intervention: adherence in delivery and uptake will be documented in the clinical record; acceptability
will be assessed during interviews.
Additionally, a series of clinical outcomes will be measured to inform outcome selection and sample size
calculation for a definitive trial. Clinical outcome measures will evaluate a range of domains.
Breathlessness
Breathlessness mastery will be assessed using the breathlessness mastery domain of the Chronic
Respiratory Disease Questionnaire [19]. NRSs will be used to investigate the following aspects of
breathlessness over the past 24 h: best breathlessness over the past 24 h, worst breathlessness over the past
TABLE 1 Schedule of events
Procedure/assessment Eligibility visit Baseline
visits
(day −8 to −1)
Study
visit 1
(day 28±3)
Study
visit 2
(day 56±7)
Study
visit 3
(day 84±3)
Study
visit 4
(day 112±3)
Inclusion/exclusion
criteria
✓
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ay
56
7
7)
Written informed consent ✓
Invitation experience
survey
✓
Vital signs ✓
Weight and height ✓
Physical examination ✓
Adverse event monitoring ✓ ✓ ✓ ✓
Spirometry ✓ ✓ ✓
Lung volume and gas
transfer measurement
✓
Questionnaires#,¶ ✓ ✓ ✓ ✓ ✓
Incremental shuttle walk
test
✓+ ✓ ✓ ✓ ✓
Activity monitoring ✓ ✓ ✓ ✓ ✓
Australia-modified KPS ✓ ✓ ✓ ✓ ✓
Healthcare utilisation ✓ ✓ ✓ ✓
Qualitative interviews§ ✓ ✓ ✓
Evaluation of usual care
received since last visit
✓ ✓ ✓ ✓ ✓
Study experience surveyƒ ✓
KPS: Karnofsky Performance Status; NRS: numerical rating scale. #: Chronic Respiratory Disease Questionnaire Dyspnoea domain,
breathlessness NRSs, St George’s Respiratory Questionnaire (idiopathic pulmonary fibrosis-specific version), EQ-5D-5L, ICECAP Supportive
Care Measure, and Hospital Anxiety and Depression Scale; ¶: the worst breathlessness in the past 24 h NRS will be completed every week for
the first 8 weeks of the trial in addition to during study visits; +: the incremental shuttle walk test will be performed on days −8 and −1 with
the result on day −1 taken as the baseline measure; §: qualitative interviews will be undertaken in a representative sample of eligible
participants and their carers (n=20), to include decliners and withdrawals, if feasible; ƒ: the study experience survey will be sent to participants
on completion of the study or, if participants discontinue the study early, as soon after withdrawal as practical.
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24 h, distress caused by breathlessness over the past 24 h and coping with breathlessness over the past
24 h. The NRSs are scored 0–10, where 0 equates to no breathlessness and 10 is the worst possible
breathlessness.
Quality of life
The St George’s Respiratory Questionnaire for patients with IPF will be used to measure disease-specific
quality of life. The EuroQol EQ-5D five-level version (EQ-5D-5L) and EQ-5D visual analogue scale
(EQ-5D-VAS) will be used to measure generic health-related quality of life.
Mood
The Hospital Anxiety and Depression Scale will be used to calculate anxiety and depression scores.
Physical activity, functional status and exercise capacity
Australian-modified Karnofsky Performance Status will be measured to assess functional status.
Exercise capacity will be assessed using the incremental shuttle walk test (performed in accordance with
European Respiratory Society/American Thoracic Society technical standards [20]). A practice incremental
shuttle walk test will be performed prior to baseline assessment to eliminate the known learning effect.
Physical activity will be measured objectively during normal daily life by asking participants to wear an
accelerometer (GT3XP-BT; ActiGraph, Pensacola, FL, USA) using an ankle strap for a period of 7 days.
Data on step counts, physical activity duration and physical activity levels will be evaluated.
Pulmonary function
Pulmonary function tests will be conducted in accordance with American Thoracic Society/European
Respiratory Society guidelines [21] at baseline and at intervals throughout the study (table 1). Lung
function is being measured to assess the number of patients with progressive disease during the trial to
inform whether this needs to be accounted for in the statistical plan for the substantive trial.
Health economics
Health service utilisation will be recorded, including: general practitioner attendance, practice nurse
attendance, outpatient appointment attendance (consultant), specialist nurse review (outpatient or home
visit), emergency department attendance, hospital admission and hospice admission. EQ-5D-5L,
EQ-5D-VAS and ICECAP Supportive Care Measure (ICECAP-SCM) data will be collected. EQ-5D-5L
data will allow the calculation of quality-adjusted life-years in a subsequent definitive trial.
Participant feedback
An invitation experience survey will be used to capture participants’ experience of the recruitment process
and evaluate reasons for individuals agreeing or declining involvement.
A study experience survey will be given to participants following completion or withdrawal from the study
to capture their overall experience of the study and reasons for withdrawal if applicable.
Qualitative substudy
A series of in-depth semistructured interviews will be performed to establish the perception of patients
and their carers about the acceptability of trial processes, study participation, the intervention and
outcome measures. Face-to-face interviews will be conducted with a purposive sample of participants
(patients and their carers). Focus groups will also be conducted with clinical team members at each site to
investigate their experience of the trial processes and the breathlessness intervention.
Data management
The main study database will be developed by the Respiratory Clinical Trials Unit at Castle Hill Hospital
(Cottingham, UK), using the commercial electronic data capture system Medrio (medrio.com). The system
uses validation and verification features that will be used to monitor study data quality, in line with the
study monitoring plan. A study monitoring plan will be developed by the sponsor quality assurance team,
in conjunction with Hull Health Trials Unit, who will assist with monitoring of the study.
Data analysis
The trial, including the flow of individual participants through each stage, will be reported in accordance
with the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement extension to pilot and
feasibility trials [22].
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For the primary outcomes, the feasibility criteria will be recruitment rate, retention rate, adverse events,
compliance and acceptability of the intervention. The recruitment rate, consisting of the eligibility and
consent rate, will be calculated with 95% confidence intervals. A table showing baseline demographic and
clinical characteristics for each group will be presented to indicate any differences between groups. Patient
characteristics will be summarised using appropriate statistics. Median (interquartile range (IQR)) will be
reported for ordinal data, mean (standard deviation) will be reported for continuous data and raw count
(number (percentage)) will be reported for nominal data.
For patient clinical outcome data, descriptive statistics will be reported: mean (standard deviation) for
continuous outcomes, median (IQR) for ordinal data and raw count (number (percentage)) for categorical
outcomes. Descriptive statistics will be presented for each group at each time-point: baseline, 4, 8, 12 and
16 weeks. The effect sizes will be calculated with 95% confidence intervals at each time-point to compare
groups. These effect sizes will be used to inform the selection of the primary end-point, primary outcome
measure and the sample size (power calculation) for the definitive randomised controlled trial.
Safety data will be summarised using descriptive statistics.
We will present health-related resource use data and health-related quality of life (EQ-5D-5L) and
wellbeing outcomes (ICECAP-SCM) for the treatment and control groups. Unit costs of health-related
resource use will be presented using published national unit cost estimates. We will generate incremental
costs and effects by comparing the treatment and control arms. Within the funding envelope available we
will not be able to conduct a full cost-effectiveness analysis using probabilistic sensitivity analysis.
Therefore, assessment of the value of conducting further research (using value of information techniques)
will not be possible. Instead, we will consider the results of the feasibility work and the potential impact
on costs and effects on wellbeing and health-related quality of life that might be shown in a larger trial.
Quantitative and qualitative data will be synthesised to address questions regarding optimal trial delivery
and most relevant primary outcome for a subsequent phase 3 trial.
Patient and public involvement
The research question was developed with input from the Hull Pulmonary Fibrosis Support Group and
members contributed to study design. A patient representative is included on the research team, and
patients directly contributed to protocol development and production of study documents, including
participant information sheets. A patient representative attends trial management group meetings and
study progress is discussed at quarterly Hull Pulmonary Fibrosis Support Group meetings. An
end-of-study report will be developed in partnership with the patient representative to allow
communication of study results to all participants.
Ethics and dissemination
Regulatory approvals and trial oversight
The trial protocol has been reviewed and approved by the Yorkshire and The Humber – Bradford Leeds
Research Ethics Committee (REC 18/YH/0147). Hull University Teaching Hospitals NHS Trust is the
study sponsor and the Hull Health Trials Unit is supporting trial delivery. A Trial Management Group has
been convened to oversee trial delivery and operations. An independent Trial Steering Committee will be
set up to provide overall supervision for the project on behalf of the project sponsor and project funder.
Safety considerations and adverse event reporting
Adverse events are defined in the full study protocol and will be reported in accordance with UK NHS
Research Ethics Service Guidelines. Hospital admission and death are common in the studied patient group
due to their underlying disease. As such, admission or death related to IPF or related comorbidities will be
classified as expected and does not require reporting within 24 h, but will be reported within 14 days.
Dissemination
Results of this feasibility study will be submitted for presentation in the form of an abstract at regional,
national and international conferences. Scientific manuscripts will be prepared and submitted for publication
in appropriate peer-reviewed journals. A lay summary will be prepared in partnership with patient and
public involvement representatives, and shared with patient groups, charities and study participants.
Discussion
The results of this feasibility study will inform the planning of a definitive randomised controlled trial
through assessing the rates of recruitment, retention, adverse events, compliance and acceptability of the
intervention. The results from this study will allow us to determine if progressing to a full-size trial using a
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complex breathlessness intervention in IPF is feasible, how many centres would be required, how the study
would need to be structured and which outcome measures would be best employed.
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